Similarly, we identify mutations in both tumor-suppressor genes, e.g., ABL1, JAK2, MAP2K1, and KIT [38], from poor responders in CML, suggesting that these are two of the key mechanisms by which tumor cells evolve to acquire drug resistance. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.